Fresenius Medical Care shares fell after the German dialysis specialist forecast flattish revenue and adjusted earnings in ...

Feb 24 (Reuters) - Fresenius Medical Care gave a cautious outlook for 2026 on Tuesday, sending its shares around 10% lower at ...

By Tristan Veyet Feb 25 (Reuters) - German healthcare group Fresenius forecast slightly higher sales for 2026 on Wednesday, falling short of market expectations, as increased market volatility and ...

A Massachusetts-based company that operates dialysis centers across the country is set to close another location in rural ...

Feb 24 (Reuters) - Fresenius Medical Care reported a sharp rise in fourth‑quarter operating income on Tuesday, helped by ...

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) used its fourth-quarter and full-year 2025 earnings call to highlight what ...

Under the collaboration, Phlow will produce the U.S.-based API, while Fresenius Kabi will manufacture the finished doses for ...

As of Tuesday, February 24, Fresenius Medical Care AG’s FMS share price has dipped by 6.71%, which has investors questioning if this is right time to buy.

The average one-year price target for Fresenius SE & Co. KGaA - Depositary Receipt (OTCPK:FSNUY) has been revised to $19.87 / share. This is a decrease of 14.55% from the prior estimate of $23.25 ...

With the former leader of the company’s pharmaceutical branch now steering Fresenius overall, new CEO Michael Sen is being frank about the need for a “reset.” The move could give the German drugmaker ...

Fresenius continues to hammer Akorn with allegations of fraud in its drug development and manufacturing as the German company battles to extract itself from its $4.3 billion buyout of the U.S. sterile ...